Racializing drug design: implications of pharmacogenomics for health disparities.

摘要: Current practices of using "race" in pharmacogenomics research demands consideration the ethical and social implications for understandings group difference efforts to eliminate health disparities. This discussion focuses on an "infrastructure racialization" created by current trajectories genetic differences among racially identified groups, use race as a proxy risk clinical practice, increasing interest new market niches pharmaceutical industry. The confluence these factors has resulted conflation genes, disease, race. I argue that public investment requires careful inequities status concerns over reifying issues distributive justice.